|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.4569 - 0.4806|
|52 Week Range||0.4550 - 1.4100|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (TBPMF), today announced a co-development agreement with Storz & Bickel to use a specialized medical device known as the Mighty Medic, in combination with its PPP001 prescription drug as well as with additional indications and a future proprietary cannabinoid formulation. The Mighty Medic is a portable herbal vaporizer for cannabis use approved by Health Canada as a Class 11 medical device and as such, is eligible for reimbursement.
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (TBPMF), today announced that the amendment of the Prescription Drug List (PDL) to include phyto-cannabinoids supports its evidence-based business model. Since early 2016 Tetra’s product development and commercialization strategy followed the exact same pathway as that used in the development of prescription drugs, namely rigorous, independently validated scientific evidence. As a biopharmaceutical company, Tetra’s orientation is to bring cannabis and cannabinoid-based products to market that meet the regulatory quality, safety and efficacy requirements for prescription medications. Health Canada recently issued a Notice of Intent to Amend the PDL to add phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids.
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (TBPMF), is pleased to announce that Mr. Richard Giguere has been hired as Executive Vice-President, Commercial Operations. Richard has more than 20 years’ experience in sales and marketing in the pharmaceutical industry from coast to coast. During his career, he has held various business development, management and negotiation positions and launched several new products on the Canadian market.
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (TBPMF), is pleased to announce that Santé Cannabis, the independently credentialed research organization they work with has finalized the clinical study protocol evaluation of PPP001, which will be the first time that cannabis is being compared to fentanyl in a clinical trial. The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada. PPP001 will investigate cannabis as an alternative to fentanyl in the management of breakthrough pain. Santé Cannabis is a Quebec-based medical clinic specialized in clinical research and cannabis - based therapies.
In Q3 of this year, TBP will file a request to commence a Phase 1 clinical trial for PPP004 our topical product indicated for General Neuropathic Pain, conservatively estimated as a billion-dollar market. Neuropathic pain can be caused by injury or disease and can be associated with such common conditions as shingles, diabetic neuropathy, multiple sclerosis, spinal stenosis and sciatica among other conditions.
ORLEANS, ON , June 12, 2018 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TBP.V) (TBPMF), a global leader in cannabinoid-based drug development and discovery, wishes to announce that Mr. André Rancourt has advised the Corporation that he will not stand for re-election to the board of directors of the Corporation due to other private business obligations to which he needs to devote his time and attention. The Corporation hereby wishes to withdraw his nomination for election as a director at the upcoming annual meeting of shareholders of the Corporation scheduled to be held on June 19, 2018 (the "Meeting"). Mr. Rancourt will remain as director of the Corporation to complete his current term, which expires at the Meeting, but will not stand for re-election.
Bob has more than 25 years’ experience in financing, including venture capital and corporate banking along with business development. During his venture days, he served on the Boards of more than 30 biotech companies and oversaw the negotiation of numerous strategic alliances with major pharmaceutical companies.
ORLEANS, ON , May 30, 2018 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TBP.V) (TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that a total of 11,500,000 common share purchase warrants (the "Warrants") of the Corporation will be listed and posted for trading under the symbol TBP.WT on the TSX Venture Exchange effective on or about June 1, 2018 . The Warrants were issued in connection with the Company's bought deal prospectus offering of Units (the "Units") that closed on March 5, 2018 . Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price equal to $1.30 at any time before March 5, 2021 .
VANCOUVER , May 17, 2018 /CNW/ - Namaste Technologies Inc. ("Namaste" or the "Company") (TSXV:N.V)(M5BQ.F)(NXTTF) is pleased to announce that the Company has signed a Supply Agreement (the "Supply Agreement") for the sale and distribution of RX Princeps the medicinal marijuana brand of Tetra Natural Health, a division of Tetra Bio-Pharma ("Tetra Bio-Pharma")(TBP.V)(TBPMF), whereby Namaste will purchase RX Princeps from Tetra Natural Health which will be sold through Namaste's wholly owned subsidiary and Access to Cannabis for Medical Purposes ("ACMPR") medical cannabis "sales-only" facility, Cannmart Inc. ("Cannmart").
Tetra Natural Health a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF) and - Namaste Technologies Inc. (“Namaste” or the “Company”) (TSX-V:N) (M5BQ.F) (NXTTF) is pleased to announce that the Company has signed a Supply Agreement ( the “Supply Agreement”) for the sale and distribution of Rx Princeps™ the medicinal cannabis brand of Tetra Natural Health, a division of Tetra Bio-Pharma (“Tetra Bio-Pharma”)(TBP.V) (TBPMF), whereby Namaste will purchase Rx Princeps™ from Tetra Natural Health which will be sold through Namaste’s wholly owned subsidiary Access to Cannabis for Medical Purposes (“ACMPR”) medical cannabis “sales-only” facility, Cannmart Inc. (“Cannmart”). The agreement also includes the sales of Tetra Natural Health’s specially designed inhalation device, air filters and its Munchies B Gone gum.
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP) (TBPMF), wishes to clarify that the annual general meeting of shareholders of the Corporation (the “Meeting”) is to be held in the City of Montréal, Québec. The Corporation noted that the notice of meeting and record date filed under the Corporation’s profile on SEDAR on April 27, 2018 incorrectly stated that the Meeting would be held in the City of Ottawa, Ontario.
Dr. Guy Chamberland, Co-Founder, Chief Scientific Officer and Interim-CEO of Tetra-Biopharma Inc. (TBPMF) (TBP.V) (“the Company”) joined Everett Jolly on Uptick Newswire’s “Stock Day” podcast to provide an update to investors and listeners on some recent company news. In the interview, Dr. Chamberland described Tetra-Biopharma as a unique and small biopharma that is developing prescription cannabis products through the FDA and Health Canada’s regular drug channels.
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), and Azevedos Indústria Farmacêutica, S.A. announced that they have signed a binding term sheet for the marketing and distribution of PPP001 in Portugal. Tetra is eligible to receive an upfront payment, milestone payments and will be paid a share of the profits generated by the sales of PPP001 in Portugal. “We are honored to partner with Azevedos, a company established in 1775, rich in tradition, and a major player in the Portuguese pharmaceutical market.
Tetra Bio-Pharma Inc. , provides a status report on its encapsulated cannabis oils clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization.
Tetra Bio-Pharma Inc. , a global leader in cannabinoid-based drug development and discovery, announced today that it has appointed Gregory Drohan to its board of directors effective April 10, 2018.
Tetra Bio-Pharma Inc. , today announced the initiation of screening and enrolment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain....
Tetra Bio-Pharma Inc. , today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer . This appointment is effective immediately....
This document corrects and replaces the press release that was sent on March 27, 2018 at 7:30 PM ET.
Tetra Bio-Pharma Inc. , a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has closed its non-brokered private placement of 4,422,000 units at a price of $1.00 ...
I am going to take a deep dive into Tetra Bio-Pharma Inc’s (TSXV:TBP) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure of aRead More...
Tetra Bio-Pharma Inc. , a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has been added to the Horizons Marijuana Life Sciences Index managed by Horizons ...
Tetra Bio-Pharma Inc. , today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary from entities controlled by Andre Rancourt, ...
Tetra Bio-Pharma Inc. , a global leader in cannabinoid-based drug development and discovery, today announced that it is conducting a non-brokered private placement of up to 4,500,000 units at a price of ...
Tetra Bio-Pharma Inc. , today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to the active ingredients of its PPP001 drug for the treatment of complex regional ...
Tetra Bio-Pharma Inc. , a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has signed a co-development and distribution partnership term sheet with a major specialty ...